

Dated: February 4, 1997.

Barbara M. McGarey,
Deputy Director, Office of Technology
Transfer.

[FR Doc. 97-3528 Filed 2-12-97; 8:45 am]

BILLING CODE 4140-01-M

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health,
Public Health Service, DHHS.
ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and a copy of the U.S. patent application referenced below may be obtained by contacting Cindy K. Fuchs, J.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7735 ext 232; fax 301/402-0220). A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

The CCHC Zinc Fingers of the Retroviral Nucleocapsid Protein Comprises a New Target Useful in Identification and Evaluation of Anti-HIV Therapeutics

L Henderson, L Arthur, W Rice, and A Rein (NCI)
Serial No. 08/379,420 filed January 27, 1995

HIV-1 contains domains known as "CCHC zinc fingers" in the retroviral nucleocapsid (NC) protein. Nucleocapsid CCHC zinc fingers are highly conserved throughout nearly all retroviruses, and are sequences of 14 amino acids with four invariant residues, Cys(X)₂Cys(X)₄His(X)₄Cys, that chelate zinc and perform essential functions in viral infectivity. HIV-1 NC has two CCHC zinc fingers, both of which are necessary for infectivity. Many compounds that disrupt the CCHC zinc fingers also inactivate HIV-1 by preventing the initiation of reverse transcription and by blocking production of infectious virus from previously infected cells by disruption of Gag processing. Compounds with this activity may be useful for developing

new types of antiretroviral drugs. The invention concerns antiretroviral compounds that disrupt the CCHC zinc fingers and assays for identifying such compounds. The invariant nature of retroviral zinc fingers extends the usefulness of these compounds to other retroviruses. Thus these assays are also useful for screening compounds effective against adult T cell leukemia, tropical spastic paraparesis caused by HTLV-1 and HTLV-II, feline leukemia virus, feline immunodeficiency virus, equine infectious virus, and lentivirus infections in other animals. This invention is available for licensing on an exclusive or non-exclusive basis.

(Portfolios: Infectious Diseases—Therapeutics, anti-virals, AIDS; Infectious Diseases—Research Materials)

Dated: February 4, 1997.

Barbara M. McGarey,
Deputy Director, Office of Technology
Transfer.

[FR Doc. 97-3529 Filed 2-12-97; 8:45 am]

BILLING CODE 4140-01-M

National Library of Medicine; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C., Appendix 2), notice is hereby given of the following National Library of Medicine Special Emphasis Panel (SEP) meeting:

Name of SEP: National Library of Medicine Special Emphasis Panel.

Date: February 10, 1997.

Time: 11:00 a.m.

Place: Conference Call, 8600 Rockville Pike, Bldg. 38A, Rm. 5S-522, Bethesda, Maryland 20894, 301/496-4221.

Contact: Dr. Roger W. Dahlen, Chief, Biomedical Information Support Branch, EP, 8600 Rockville Pike, Bldg. 38A, Rm. 5S-522, Bethesda, Maryland 20894, 301/496-4221.

Purpose/Agenda: To evaluate and review Fellowship grant applications. The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program No. 93-879—Medical Library Assistance, National Institutes of Health)

Dated: February 7, 1997.

LaVerne Y. Stringfield,
Committee Management Officer, NIH.
[FR Doc. 97-3631 Filed 2-10-97; 2:31 pm]

BILLING CODE 4140-01-M

Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Chemistry and Related Sciences.

Date: March 6-8, 1997.

Time: 8:00 a.m.

Place: Redlion Inn, Richland, Washington.
Contact Person: Dr. Marjam Behar, Scientific Review Administrator, 6701 Rockledge Drive, Room 5218, Bethesda, Maryland 20892, (301) 435-1180.

Name of SEP: Clinical Sciences.

Date: March 20, 1997.

Time: 8:00 a.m.

Place: Holiday Inn, Chevy chase, Maryland.

Contact Person: Ms. Josephine Pelham, Scientific Review Administrator, 6701 Rockledge Drive, Room 4106, Bethesda, Maryland 20892, (301) 435-1786.

Name of SEP: Biological and Physiological Sciences.

Date: March 20, 1997.

Time: 3:00 p.m.

Place: NIH, Rockledge 2, Room 4144, Telephone Conference.

Contact Person: Dr. Paul Strudler, Scientific Review Administrator, 6701 Rockledge Drive, Room 4144, Bethesda, Maryland 20892, (301) 435-1716.

Name of SEP: Microbiological and Immunological Sciences.

Date: March 24-25, 1997.

Time: 8:30 a.m.

Place: Doubletree Hotel, Rockville, Maryland.

Contact Person: Dr. Garrett Keefer, Scientific Review Administrator, 6701 Rockledge Drive, Room 4190, Bethesda, Maryland 20892, (301) 435-1152.

Name of SEP: Chemistry and Related Sciences.

Date: April 14-16, 1997.

Time: 4:00 p.m.

Place: Hampton Inn, Urbana, Illinois.
Contact Person: Dr. Nancy Lamontagne, Scientific Review Administrator, 6701 Rockledge Drive, Room 4170, Bethesda, Maryland 20892, (301) 435-1726.

Name of SEP: Clinical Sciences.

Date: April 18, 1997.

Time: 11:00 a.m.

Place: NIH, Rockledge 2, Room 4126, Telephone Conference.

Contact Person: Dr. Jerrold Fried, Scientific Review Administrator, 6701 Rockledge Drive, Room 4126, Bethesda, Maryland 20892, (301) 435-1777.